VolitionRx (NYSE:VNRX) Receives Buy Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of VolitionRx (NYSE:VNRX) in a research report released on Monday,Benzinga reports. They currently have a $5.00 price target on the stock.

Separately, Jones Trading raised shares of VolitionRx to a “strong-buy” rating and set a $3.00 price target on the stock in a report on Tuesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, VolitionRx has an average rating of “Buy” and a consensus target price of $3.50.

VolitionRx Stock Up 3.0%

Shares of NYSE:VNRX opened at $0.62 on Monday. The company has a market capitalization of $67.03 million, a price-to-earnings ratio of -1.73 and a beta of 1.27. VolitionRx has a 52 week low of $0.40 and a 52 week high of $0.94. The firm has a 50 day moving average of $0.66 and a 200 day moving average of $0.60.

Insiders Place Their Bets

In related news, Director Guy Archibald Innes acquired 78,125 shares of the company’s stock in a transaction dated Tuesday, August 5th. The shares were purchased at an average cost of $0.64 per share, with a total value of $50,000.00. Following the completion of the acquisition, the director directly owned 966,814 shares of the company’s stock, valued at $618,760.96. This represents a 8.79% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Cameron John Reynolds acquired 78,125 shares of the company’s stock in a transaction dated Tuesday, August 5th. The shares were bought at an average cost of $0.64 per share, for a total transaction of $50,000.00. Following the completion of the acquisition, the chief executive officer directly owned 2,609,847 shares of the company’s stock, valued at approximately $1,670,302.08. The trade was a 3.09% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 171,250 shares of company stock worth $109,900 over the last three months. Corporate insiders own 10.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in VNRX. Northern Trust Corp lifted its position in VolitionRx by 32.0% during the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after purchasing an additional 28,579 shares during the period. Millennium Management LLC acquired a new position in VolitionRx during the fourth quarter valued at $36,000. Silverberg Bernstein Capital Management LLC lifted its position in VolitionRx by 42.8% during the second quarter. Silverberg Bernstein Capital Management LLC now owns 200,782 shares of the company’s stock valued at $153,000 after purchasing an additional 60,209 shares during the period. Blair William & Co. IL acquired a new position in VolitionRx during the second quarter valued at $30,000. Finally, Northwestern Mutual Wealth Management Co. acquired a new position in VolitionRx during the second quarter valued at $52,000. 8.09% of the stock is currently owned by institutional investors and hedge funds.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.